Which has stronger earnings and valuation, DYN or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is DYN or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Design Therapeutics N/A -33.07% -31.29%

Is ALMS or DSGN more profitable?

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Design Therapeutics' return on equity of -33.07% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Design Therapeutics N/A -33.07% -31.29%

Do analysts prefer DSGN or GMTX?

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 7.00%. Given Design Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Design Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, DSGN or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is DSGN or GMTX more profitable?

Design Therapeutics' return on equity of -33.07% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Gemini Therapeutics N/A -38.78% -35.88%

Design Therapeutics (DSGN) Competitors

$15.42 +0.14 (+0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$14.85 -0.57 (-3.72%)

As of 07:21 PM Eastern

Compare

DSGN vs. DYN, ALMS, ADPT, ARQT, and GMTX

Should you buy Design Therapeutics stock or one of its competitors? MarketBeat compares Design Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Design Therapeutics include Dyne Therapeutics (DYN), Alumis (ALMS), Adaptive Biotechnologies (ADPT), Arcutis Biotherapeutics (ARQT), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Design Therapeutics compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Design Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Dyne Therapeutics had 9 more articles in the media than Design Therapeutics. MarketBeat recorded 9 mentions for Dyne Therapeutics and 0 mentions for Design Therapeutics. Dyne Therapeutics' average media sentiment score of 0.36 beat Design Therapeutics' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dyne Therapeutics	Neutral
Design Therapeutics	Neutral

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Design Therapeutics' return on equity of -33.07% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Design Therapeutics	N/A	-33.07%	-31.29%

Dyne Therapeutics presently has a consensus price target of $34.17, suggesting a potential upside of 40.78%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 7.00%. Given Dyne Therapeutics' higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Dyne Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Summary

Dyne Therapeutics and Design Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

56.6% of Design Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alumis presently has a consensus price target of $40.30, suggesting a potential upside of 33.00%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 7.00%. Given Alumis' higher probable upside, research analysts clearly believe Alumis is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Alumis had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Alumis and 0 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.00 beat Alumis' score of -0.06 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alumis	Neutral
Design Therapeutics	Neutral

Design Therapeutics has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	160.62	-$243.32M	-$1.98	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Alumis has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Design Therapeutics' return on equity of -33.07% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Design Therapeutics	N/A	-33.07%	-31.29%

Summary

Design Therapeutics beats Alumis on 10 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Design Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Design Therapeutics' return on equity of -33.07% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Design Therapeutics	N/A	-33.07%	-31.29%

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adaptive Biotechnologies has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Adaptive Biotechnologies currently has a consensus target price of $20.83, indicating a potential downside of 4.43%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 7.00%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Adaptive Biotechnologies has higher revenue and earnings than Design Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	12.60	-$59.50M	-$0.33	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Adaptive Biotechnologies had 17 more articles in the media than Design Therapeutics. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 0 mentions for Design Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.32 beat Design Therapeutics' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adaptive Biotechnologies	Neutral
Design Therapeutics	Neutral

Summary

Adaptive Biotechnologies and Design Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Arcutis Biotherapeutics?

Design Therapeutics (NASDAQ:DSGN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Arcutis Biotherapeutics has higher revenue and earnings than Design Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Arcutis Biotherapeutics	$376.07M	9.57	-$16.14M	-$0.03	N/A

Design Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 0 mentions for Design Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.47 beat Design Therapeutics' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Design Therapeutics	Neutral
Arcutis Biotherapeutics	Neutral

Design Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 7.00%. Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 18.14%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Design Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

56.6% of Design Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Design Therapeutics and Arcutis Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Gemini Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Design Therapeutics' return on equity of -33.07% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Gemini Therapeutics	N/A	-38.78%	-35.88%

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 7.00%. Given Design Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Design Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

In the previous week, Gemini Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Company	Overall Sentiment
Design Therapeutics	Neutral
Gemini Therapeutics	Neutral

Design Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Summary

Design Therapeutics beats Gemini Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$954.34M	$3.78B	$6.93B	$12.49B
Dividend Yield	N/A	2.18%	2.68%	7.79%
P/E Ratio	-12.85	21.70	27.39	24.62
Price / Sales	N/A	330.40	534.92	108.47
Price / Cash	N/A	145.39	48.45	59.17
Price / Book	4.13	8.62	11.02	6.46
Net Income	-$69.79M	$23.85M	$3.57B	$331.60M
7 Day Performance	-1.41%	0.94%	0.41%	-0.42%
1 Month Performance	46.16%	12.09%	5.76%	2.09%
1 Year Performance	269.78%	57.06%	31.25%	22.24%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	1.2045 of 5 stars	$15.42 +0.9%	$16.50 +7.0%	+319.8%	$954.34M	N/A	N/A	40
DYN Dyne Therapeutics	2.9023 of 5 stars	$22.21 +4.5%	$34.17 +53.8%	+184.0%	$3.51B	N/A	N/A	100	Analyst Upgrade Insider Trade
ALMS Alumis	2.9782 of 5 stars	$28.14 +3.7%	$40.30 +43.2%	+754.6%	$3.46B	$24.05M	N/A	N/A	News Coverage Analyst Forecast Insider Trade
ADPT Adaptive Biotechnologies	2.4318 of 5 stars	$21.45 +0.2%	$20.50 -4.4%	+71.7%	$3.42B	$276.98M	N/A	790	Positive News Analyst Forecast Insider Trade
ARQT Arcutis Biotherapeutics	2.8945 of 5 stars	$26.22 -2.0%	$34.00 +29.7%	+107.1%	$3.35B	$376.07M	N/A	150	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. DYN, ALMS, ADPT, ARQT, and GMTX

How does Design Therapeutics compare to Dyne Therapeutics?

Summary

How does Design Therapeutics compare to Alumis?

Summary

How does Design Therapeutics compare to Adaptive Biotechnologies?

Summary

How does Design Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Design Therapeutics compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. DYN, ALMS, ADPT, ARQT, and GMTX

How does Design Therapeutics compare to Dyne Therapeutics?

Which has stronger earnings and valuation, DYN or DSGN?

Does the media refer more to DYN or DSGN?

Do institutionals & insiders hold more shares of DYN or DSGN?

Is DYN or DSGN more profitable?

Do analysts prefer DYN or DSGN?

Which has more volatility & risk, DYN or DSGN?

Summary

How does Design Therapeutics compare to Alumis?

Do institutionals & insiders have more ownership in ALMS or DSGN?

Do analysts rate ALMS or DSGN?

Does the media refer more to ALMS or DSGN?

Which has stronger valuation and earnings, ALMS or DSGN?

Which has more risk & volatility, ALMS or DSGN?

Is ALMS or DSGN more profitable?

Summary

How does Design Therapeutics compare to Adaptive Biotechnologies?

Is ADPT or DSGN more profitable?

Do institutionals and insiders believe in ADPT or DSGN?

Which has more risk and volatility, ADPT or DSGN?

Do analysts rate ADPT or DSGN?

Which has higher valuation and earnings, ADPT or DSGN?

Does the media refer more to ADPT or DSGN?

Summary

How does Design Therapeutics compare to Arcutis Biotherapeutics?

Which has stronger earnings and valuation, DSGN or ARQT?

Which has more volatility & risk, DSGN or ARQT?

Does the media prefer DSGN or ARQT?

Do analysts recommend DSGN or ARQT?

Is DSGN or ARQT more profitable?

Do institutionals & insiders believe in DSGN or ARQT?

Summary

How does Design Therapeutics compare to Gemini Therapeutics?

Is DSGN or GMTX more profitable?

Do insiders & institutionals believe in DSGN or GMTX?

Do analysts prefer DSGN or GMTX?

Which has better earnings & valuation, DSGN or GMTX?

Does the media prefer DSGN or GMTX?

Which has more volatility and risk, DSGN or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools